Leadership

CEO

Mr. Peter Mørch Eriksen

Peter Mørch Eriksen was appointed CEO of BioPorto in July 2013. Peter Mørch Eriksen has more than 15 years of experience within medtech/life science in Denmark and abroad. Prior to joining BioPorto, Peter Mørch Eriksen was CEO of Sense A/S and before this, he held positions as Vice President of Medtronic in both the USA and Denmark. From these positions Peter Mørch Eriksen brings extensive experience in creating growth, restructuring and funding in technology intensive and complex companies. Peter Mørch Eriksen has an accounting background supplemented with courses in management. In addition to being CEO of BioPorto, Peter Mørch Eriksen chairs the board of MTIC, is a board member at Nervex A/S, member of Lund University Advisory Board, and Director of PMEconsult ApS. He also serves on the Medical Device and Diagnostics Advisory Committee of Cincinnati Children’s Hospital Medical Center in Ohio, US.

  LinkedIN Profile

management
CFO

MR. OLE LARSEN

Ole Larsen was appointed CFO of BioPorto in June 2018. Ole Larsen brings comprehensive industrial and financial knowledge to BioPorto as an experienced executive in international health care and media companies. Most recently from Bavarian Nordic A/S, a NASDAQ-listed Danish biotechnology company focused on cancer immunotherapies and vaccines for infectious diseases. Since 2008, Ole Larsen served as Executive Vice President and CFO and was responsible for Finance, IR and IT. Prior to this, Ole Larsen held CFO positions at two of the largest Danish and Nordic media groups, Nordisk Film and Berlingske Tidende. Ole Larsen holds a MSc in Economics from Copenhagen Business School.

LinkedIN Profile

management
COO

Mr. Jan Kuhlmann Andersen

Jan Kuhlmann Andersen was appointed COO of BioPorto in August 2016. Jan Kuhlmann Andersen is a very experienced executive having worked with sales within the life sciences area, mostly in US-owned companies such as FMC, Cambrex, Fisher Scientific and Thermo Fisher Scientific since 1995. From 2007 and until joining BioPorto, Jan Kuhlmann Andersen was Vice President, sales & marketing, in the Animal Health & Nutrition division in Chr. Hansen A/S. Jan Kuhlmann Andersen holds a PhD in immunology and a MSc in Biology, both from the University of Copenhagen. Jan Kuhlmann Andersen also serves as the Chairman of Cytovac A/S and was previously board member of Noscomed Medical Supply A/S, the French life science company Cell Made and of BioPorto A/S from 2015 to 2016.

 LinkedIN Profile

management
Chairman of the board

Mr. Thomas Magnussen

MBA from INSEAD and PhD and MSc from the Technical University of Denmark

Chairman and Board member since 2013 

Thomas Magnussen is Chairman and co-founder and partner in QuantumWise A/S and Zylinc A/S respectively as well as an entrepreneur in the high-tech space, engaging in start-up companies with global business scope. Thomas Magnussen has experience in commercialization strategies and from industries including nanotechnology, ICT and medtech.

  LinkedIN Profile
 

management
Vice chairman of the board

Mr. Torben A. Nielsen

DIEUs top management education, VL and banking education 

Board member since 2013 

Torben A. Nielsen has for more than 25 years held senior positions in the financial sector. From 1998 to 2008 he was member of the executive management in Sydbank A/S responsible for asset management, capital markets, treasury, foreign and several other business areas, and from 2008 to 2012 he was the CEO of BankInvest A/S. Concurrently, he has held several national and international board positions, including at NASDAQ OMX. Of a total of 30 years in the financial sector, of which 5 years in New York and London, Torben A. Nielsen built and managed businesses at home and abroad in all relevant commercial business areas in the financial sector and has been involved in and responsible for several mergers and acquisitions.

  LinkedIN Profile

management
Board member

Mrs. Kirsten Aarup Drejer

MSc and PhD in pharmacology from the University of Copenhagen.

Board member since 2017.

Kirsten Aarup Drejer is co-founder of Symphogen A/S, a biopharmaceutical company focused on the innovative therapeutic utilization of antibodies. In the period from 2000 until 2016, Kirsten Aarup Drejer was CEO of Symphogen A/S. Before this, Kirsten Aarup Drejer held a number of scientific and managerial positions within Novo Nordisk A/S. Kirsten Aarup Drejer is a member of the board of directors of Symphogen A/S and the Danish Growth Fund and has previously been a member of the board of directors of, among others, Danisco A/S. Kirsten Aarup Drejer is a member of numerous advisory boards at the University of Copenhagen and the Copenhagen Business School. Kirsten Aarup Drejer won the prize of ”BiotechBuilder of the Year” in 2003 and ”Entrepreneur of the Year, Biotech” in 2007. 

  LinkedIN Profile

 

 

management